Clinical Trial Search

Primary: Progression-free Survival (PFS) > 6 Months — 17.8 percentage of participants

Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients

Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants

Primary: To Evaluate the Toxicity and Tolerability of Pelvic Radiation "Sandwiched" Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC — 65.5; 25.8…

Primary: Nature and Degree of Toxicity — 2; 4; 20; 19 Participants

Primary: Progression Free Survival Differences Between Treatment Arms. — 8.049; 12.945 months

Primary: Number of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 2; 0 participants

Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants

Primary: Number of Participants With Overall Response — 8 participants

Primary: Objective Response Rates (ORR) — 74.4 percentage of participants

Primary: Overall Survival Rate at 5 Years — 71; 72 Percentage of participants

Primary: Number of Patients Completing the Protocol — 27 Participants

Primary: Objective Response Rate (ORR) — 26 Percentage of participants

Primary: Objective Overall Response Rate — 2; 0 participants

Primary: Objective Response Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Among Patients With Advanced Leiomyosarcoma of the Uterus (ULMS) Treated With Nivolumab…

Primary: Evaluate Patients With Progression Free Survival (PFS) — 26 months

Primary: 3-year Overall Survival — 17 partipants

Primary: Pelvic Recurrence Rate at 3 Years — 2.17; 2.52 percentage of participants

Primary: Number of Patients With Measurable Concentration of Gemcitabine in Uterine Vein (dFdC) — 5 Participants

Primary: Number of Participants With Progressive Disease or Death Due to Any Cause at 3 Years — 55; 83; 149; 141 participants — p=0.029

Primary: Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor…

Primary: Disease-free Survival (Percentage of Participants Alive Without Disease) — 86.4; 82.1; 76.2; 76.9 percentage of participants — p=0.56

Primary: Safety as Measured by Any Grade Treatment Related Adverse Events Experienced by ≥ 2 Patients — 10; 9; 8; 8 Participants

Primary: Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 1; 16 participants

Primary: Toxicity (Number of Participants With Serious Adverse Events) — 10 Participants

Primary: Overall Survival — 21.9; 19.5 months — p=0.125

Primary: Anti-tumor Activity as Measured by Surviving Progression-free — 59 percentage of participants

Primary: Overall Survival — 13.43; 7.62 months

Primary: Proportion of Patients Who Are Progression-free at 6 Months — 0.29 Proportion of patients

Primary: Feasibility of Acquiring In-vivo High-Resolution Microendoscopy (HRME) Images of Cervix Prior to Conization